Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care : confirms illegal publication of patient data in Serbia subsequent to recent hacker attack

share with twitter share with LinkedIn share with facebook
05/21/2020 | 08:10am EDT

Press Release

May 21, 2020

Media Contact

Matthias Link

  1. +49 6172 609-2872matthias.link@fmc-ag.com

Contact for analysts and investors

Dr. Dominik Heger

  1. +49 6172 609-2601dominik.heger@fmc-ag.com

www.freseniusmedicalcare.com

Fresenius Medical Care confirms illegal publication of patient data

in Serbia subsequent to recent hacker attack

Fresenius Medical Care, the world's largest provider of dialysis products and services, is aware that patient data from some of the company's dialysis centers in Serbia has been published by unauthorized persons. The company's understanding is that this is associated with the IT incident which affected parts of Fresenius's IT environment a few weeks ago and that hackers were able to steal certain data. The investigation is ongoing.

Fresenius Medical Care has immediately filed a complaint against the unknown attackers with the public prosecutor in Germany. The company is committed to fully cooperate with the relevant authorities. Furthermore, the company will contact the patients who are affected by the illegal data publication.

The company's operations in Serbia continue and the care of patients has been safeguarded.

The company deeply regrets this invasion of some patients' privacy, is doing its utmost to prevent further data to be published and to save affected patients and other stakeholders from harm.

Internal and external specialists are continuously working to prevent further potential attacks or unauthorized data access.

Page 1/2

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,002 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 348,703 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company's website at www.freseniusmedicalcare.com.

Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Page 2/2

Disclaimer

FMC - Fresenius Medical Care AG & Co. KGaA published this content on 21 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 May 2020 11:09:08 UTC


share with twitter share with LinkedIn share with facebook
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
10/26FMC FRESENIUS MEDICAL CARE AG & CO K : JP Morgan gives a Buy rating
MD
10/26FRESENIUS SE : Buy rating from JP Morgan
MD
10/26FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from Goldman Sachs
MD
10/26FMC FRESENIUS MEDICAL CARE AG & CO K : Berenberg gives a Buy rating
MD
10/23FRESENIUS SE : Receives a Buy rating from Goldman Sachs
MD
10/23FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Buy rating from Goldman Sachs
MD
10/22FRESENIUS SE : Credit Suisse reiterates its Neutral rating
MD
10/22FMC FRESENIUS MEDICAL CARE AG & CO K : Credit Suisse reaffirms its Neutral ratin..
MD
10/22FMC FRESENIUS MEDICAL CARE AG & CO K : Credit Suisse remains Neutral
MD
10/21FRESENIUS SE : Berenberg reiterates its Buy rating
MD
More news
Financials (USD)
Sales 2020 21 511 M - -
Net income 2020 1 549 M - -
Net Debt 2020 14 311 M - -
P/E ratio 2020 15,3x
Yield 2020 1,75%
Capitalization 23 755 M 23 774 M -
EV / Sales 2020 1,77x
EV / Sales 2021 1,65x
Nbr of Employees 124 736
Free-Float 65,1%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 97,67 $
Last Close Price 81,12 $
Spread / Highest target 41,5%
Spread / Average Target 20,4%
Spread / Lowest Target -21,6%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer